scholarly journals A Case of Chronic Neutrophilic Leukemia Successfully Treated with Pegylated Interferon Alpha-2a

2015 ◽  
Vol 8 ◽  
pp. CCRep.S22820 ◽  
Author(s):  
Mohamed A. Yassin ◽  
Samah Kohla ◽  
Ahmad Al-Sabbagh ◽  
Ashraf T. Soliman ◽  
Anil Yousif ◽  
...  
Keyword(s):  
Growth Factor ◽  
Interferon Alpha ◽  
Complete Blood Count ◽  
Myeloproliferative Neoplasm ◽  
Growth Factor Receptor ◽  
Pegylated Interferon ◽  
Janus Kinase ◽  
Pegylated Interferon Alpha ◽  
Chronic Neutrophilic Leukemia ◽  
First Case

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm (MPN) that represents a diagnostic dilemma for both clinicians and pathologists. Because this disease entity is very rare, and because its diagnosis is by exclusion, it is important for clinical hematologists and hemato-pathologists to be familiar with CNL when approaching patients with MPNs and persistent neutrophilia. A woman in her 40s who was incidentally found to have leukocytosis was referred to the hematology service at the National Center for Cancer Care and Research for evaluation. Complete blood count revealed hyperleukocytosis with predominant neutrophilia. Peripheral blood and flow cytometry did not show any evidence of lymphoproliferative disorder or myeloblasts. Bone marrow aspirate and biopsy revealed a hypercellular marrow with myeloid hyperplasia. Cytogenetics revealed normal karyotype. Tests for both Janus kinase mutation JAK2 V617F and rearrangement of the genes BCR–ABL1, platelet-derived growth factor receptor-α (PDGFRα), PDGFRβ, and fibroblast growth factor receptor-1 (FGFR1) were negative. Thereafter, the diagnosis of CNL was reached. She was treated with pegylated interferon alpha-2a, with very good hematological response. To the best of our knowledge, this is the first case of CNL reported among the Arab population.

scholarly journals Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C

2006 ◽  
Vol 20 (10) ◽  
pp. 661-663 ◽  
Author(s):  
Yvette Leung ◽  
Stefan J Urbanski ◽  
Lynn Schindel ◽  
Robert P Myers
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Ischemic Colitis ◽  
Infected Patient ◽  
Metastatic Cancer ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
First Case

Rare cases of ischemic colitis associated with interferon-alpha (IFN-α) treatment for chronic hepatitis C (HCV) infection and metastatic cancer have been reported. The present study describes the first case of ischemic colitis attributable to pegylated IFN-α and ribavirin combination therapy in an HCV-infected patient after 34 weeks of treatment. The clinical presentation, endoscopic appearance and histopathology of the colon were consistent with ischemic colitis, and the patient’s symptoms rapidly resolved with cessation of therapy. The association between the therapy and the pathogenesis of ischemic colitis is unclear, but immunoregulatory, vasospastic and procoagulant mechanisms have been proposed. Physicians should be aware of this complication, and should consider it in any HCV-infected patient taking pegylated IFN-α and ribavirin who develops abdominal discomfort and gastrointestinal bleeding.

scholarly journals Novel drug for COVID-19: Virafin a therapeutic breakthrough

2021 ◽  
Vol 8 (1) ◽  
pp. 12-14
Author(s):  
J Robinson ◽  
I Banerjee ◽  
B Roy ◽  
A Leclézio
Keyword(s):  
Polyethylene Glycol ◽  
Interferon Alpha ◽  
Oxygen Therapy ◽  
Pegylated Interferon ◽  
Janus Kinase ◽  
Human Interferon ◽  
Pegylated Interferon Alpha ◽  
Interferon Alpha 2B ◽  
Interferon Receptor ◽  
2B Protein

Background: Pegylated Interferon Alpha-2b is synthesized via the use of PEG (polyethylene glycol). It is formulated via attaching a 12kDa mono methoxy polyethylene glycol moiety to the recombinant human Interferon Alpha-2b protein. Pegylated Interferon Alpha-2b acts via binding to the (JAK/STAT) Janus kinase signal transducer and activator of the transcription interferon receptor. The Pegylated Interferon Alpha-2b /Virafin binds to the (IFNAR1/2) alpha interferon receptor 1 and 2. Pegylated Interferon Alpha-2b better known as Virafin has been approved by the Drugs Controller General of India. This therapeutic agent is currently under a multicentric phase 3 trial with very promising results being reported. A single subcutaneous dose of Virafin has been shown to decrease the need for oxygen therapy in patients. This reduction in the need for oxygen therapy is a vital factor needed to provide relief to the Indian medical system in light of the recent oxygen shortages faced due to India’s worst wave of COVID-19 cases since the onset of the global pandemic. Pegylated Interferon Alpha-2b/ Virafin confers enhanced viral clearance and bolsters the immune response to induce a quicker recovery in patients with mild to moderate symptoms. Conclusion: It is of paramount importance that further research on Virafin is undertaken as it can hinder the progression of COVID-19, reduce pressure on the inundated health systems, and save countless lives.

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1

2016 ◽  
Vol 25 (1) ◽  
pp. 15-24 ◽  
Author(s):  
Tim Zimmermann ◽  
Dietrich Hueppe ◽  
Stefan Mauss ◽  
Peter Buggisch ◽  
Heike Pfeiffer-Vornkahl ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Interferon Alpha ◽  
Virological Response ◽  
Sustained Viral Response ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Pegylated Interferon Alpha ◽  
Viral Response

Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on hepatitis C virus antiviral therapy. Methods: Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed. Results: In the univariate matched pair analysis of dual antiviral therapy patients (n=584), smoking was significantly associated with lower sustained viral response rates (p=0.026, OR 0.69 CI: 0.50 – 0.96). The effect of smoking on sustained viral response remained significant (p=0.028, OR 0.67 CI: 0.47 – 0.96) in the multivariate analysis when adjusting for all other baseline parameters with a significant association in the univariate analysis, i.e. diabetes, fibrosis, body mass index, transaminases and baseline viral load. Under protease inhibitors the influence of smoking on virological response did not arise. Conclusions: Smoking has a negative impact on antiviral therapy in naïve patients infected with HCV genotype 1 independently of age, gender, history of drug use or alcoholic liver disease. The effects of smoking might be overcome by the new antiviral agents.Abbreviations: APRI: AST to platelet ratio index; DAA: direct antiviral agent; DT: dual antiviral therapy; EoTR: end of treatment response; RVR: rapid virological response; EVR: early virological response; HCV: hepatitis C virus; IFN: interferon alpha; MPA: Matched Pair Analysis; NS: non-smokers; PEG-IFN: pegylated interferon alpha 2a; PI: protease inhibitor; RBV: ribavirin; SAE: serious adverse event; SOC: standard of care; S: smokers; SVR: sustained viral response.    

Pegylated interferon alpha 2b for chronic hepatitis C

2009 ◽  
Author(s):  
Tahany Awad ◽  
Kristian Thorlund ◽  
Goran Hauser ◽  
Mahasen Mabrouk ◽  
Davor Stimac ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Interferon Alpha 2B

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

2003 ◽  
Vol 51 (1) ◽  
pp. 81-86 ◽  
Author(s):  
Yesid Alvarado ◽  
Jorge Cortes ◽  
Srdan Verstovsek ◽  
Deborah Thomas ◽  
Stephan Faderl ◽  
...  
Keyword(s):  
Pilot Study ◽  
Interferon Alpha ◽  
Essential Thrombocythemia ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Interferon Alpha 2B
Sign in / Sign up

Export Citation Format

Share Document